Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.54 |
| ▸ | DRD1 | P21728 | 2/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DRD5 | P21918 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.43 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.43 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.43 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.43 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.43 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.43 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.43 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.43 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | MLNR | O43193 | 4/20 | 0.42 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5325264 | 0.82 | ADCY6 (0.49) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL5327478 | 0.80 | APP (0.52) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL5325119 | 0.78 | KDM4E (0.50) | HTR1BHTR2BHTR2CHTR2ASLC6A2 | |
| SCHEMBL4030395 | 0.75 | DRD2 (0.79) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL31317940 | 0.75 | DRD2 (0.79) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL30979264 | 0.75 | ENPP2 (0.65) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL70267 | 0.75 | ENPP2 (0.65) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL4179106 | 0.75 | HTR2C (0.46) | DRD2DRD1HTR2BHTR2CHTR2A | |
| SCHEMBL18766202 | 0.74 | HTR2C (0.52) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL29321156 | 0.74 | PARP11 (0.54) | DRD2DRD3HTR2BHTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007149728-A2 | ARYL AND HETEROARYL TETRAHYDROBENZAZEPINE DERIVATIVES AND THEIR USE FOR TREATING GLAUCOMA | ALCON RESEARCH, LTD. (US) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007149728-A2 | ARYL AND HETEROARYL TETRAHYDROBENZAZEPINE DERIVATIVES AND THEIR USE FOR TREATING GLAUCOMA | ALCON RESEARCH, LTD. (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20070293475-A1 | ARYL AND HETEROARYL TETRAHYDROBENZAZEPINE DERIVATIVES AND THEIR USE FOR TREATING GLAUCOMA | ALCON MANUFACTURING LTD. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293475-A1 | ARYL AND HETEROARYL TETRAHYDROBENZAZEPINE DERIVATIVES AND THEIR USE FOR TREATING GLAUCOMA | ALCON MANUFACTURING LTD. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293475-A1 | ARYL AND HETEROARYL TETRAHYDROBENZAZEPINE DERIVATIVES AND THEIR USE FOR TREATING GLAUCOMA | ALCON MANUFACTURING LTD. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293475-A1 | ARYL AND HETEROARYL TETRAHYDROBENZAZEPINE DERIVATIVES AND THEIR USE FOR TREATING GLAUCOMA | HTR2B, HTR2A, HTR3B | DRD2 72/4885DRD1 346/4885DRD4 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.